Literature DB >> 9113993

Purification and characterization of a human RNA adenosine deaminase for glutamate receptor B pre-mRNA editing.

J H Yang1, P Sklar, R Axel, T Maniatis.   

Abstract

The glutamate receptor subunit B (GluR-B) pre-mRNA is edited at two adenosine residues, resulting in amino acid changes that alter the electrophysiologic properties of the glutamate receptor. Previous studies showed that these amino acid changes are due to adenosine to inosine conversions in two codons resulting from adenosine deamination. Here, we describe the purification and characterization of an activity from human HeLa cells that efficiently and accurately edits GluR-B pre-mRNA at both of these sites. The purified activity contains a human homolog of the recently reported rat RED1 (rRED1) protein, a member of the family of double-stranded RNA-dependent deaminase proteins. Recombinant human RED1 (hRED1), but not recombinant dsRAD, another member of the family, efficiently edits both the Q/R and R/G sites of GluR-B RNA. We conclude that the GluR-B editing activity present in HeLa cell extracts and the recombinant hRED1 protein are indistinguishable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9113993      PMCID: PMC20726          DOI: 10.1073/pnas.94.9.4354

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Ca2+ permeability of KA-AMPA--gated glutamate receptor channels depends on subunit composition.

Authors:  M Hollmann; M Hartley; S Heinemann
Journal:  Science       Date:  1991-05-10       Impact factor: 47.728

2.  Structural determinants of ion flow through recombinant glutamate receptor channels.

Authors:  T A Verdoorn; N Burnashev; H Monyer; P H Seeburg; B Sakmann
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

3.  RNA editing in brain controls a determinant of ion flow in glutamate-gated channels.

Authors:  B Sommer; M Köhler; R Sprengel; P H Seeburg
Journal:  Cell       Date:  1991-10-04       Impact factor: 41.582

Review 4.  The TINS/TiPS Lecture. The molecular biology of mammalian glutamate receptor channels.

Authors:  P H Seeburg
Journal:  Trends Neurosci       Date:  1993-09       Impact factor: 13.837

5.  RNA editing of AMPA receptor subunit GluR-B: a base-paired intron-exon structure determines position and efficiency.

Authors:  M Higuchi; F N Single; M Köhler; B Sommer; R Sprengel; P H Seeburg
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

Review 6.  RNA editing. RNA duplexes guide base conversions.

Authors:  R Cattaneo
Journal:  Curr Biol       Date:  1994-02-01       Impact factor: 10.834

7.  Control of kinetic properties of AMPA receptor channels by nuclear RNA editing.

Authors:  H Lomeli; J Mosbacher; T Melcher; T Höger; J R Geiger; T Kuner; H Monyer; M Higuchi; A Bach; P H Seeburg
Journal:  Science       Date:  1994-12-09       Impact factor: 47.728

8.  Determinants of Ca2+ permeability in both TM1 and TM2 of high affinity kainate receptor channels: diversity by RNA editing.

Authors:  M Köhler; N Burnashev; B Sakmann; P H Seeburg
Journal:  Neuron       Date:  1993-03       Impact factor: 17.173

Review 9.  RNA editing: exploring one mode with apolipoprotein B mRNA.

Authors:  L Chan
Journal:  Bioessays       Date:  1993-01       Impact factor: 4.345

10.  Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit.

Authors:  N Burnashev; H Monyer; P H Seeburg; B Sakmann
Journal:  Neuron       Date:  1992-01       Impact factor: 17.173

View more
  21 in total

1.  A phylogenetic analysis reveals an unusual sequence conservation within introns involved in RNA editing.

Authors:  P J Aruscavage; B L Bass
Journal:  RNA       Date:  2000-02       Impact factor: 4.942

2.  Increased RNA editing and inhibition of hepatitis delta virus replication by high-level expression of ADAR1 and ADAR2.

Authors:  Geetha C Jayan; John L Casey
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Transcriptome-wide identification of A > I RNA editing sites by inosine specific cleavage.

Authors:  Pierre B Cattenoz; Ryan J Taft; Eric Westhof; John S Mattick
Journal:  RNA       Date:  2012-12-21       Impact factor: 4.942

4.  Widespread inosine-containing mRNA in lymphocytes regulated by ADAR1 in response to inflammation.

Authors:  Jing-Hua Yang; Xiaoxing Luo; Yongzhan Nie; Yingjun Su; Qingchuan Zhao; Koroush Kabir; Dexin Zhang; Reuven Rabinovici
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

5.  dADAR, a Drosophila double-stranded RNA-specific adenosine deaminase is highly developmentally regulated and is itself a target for RNA editing.

Authors:  M J Palladino; L P Keegan; M A O'Connell; R A Reenan
Journal:  RNA       Date:  2000-07       Impact factor: 4.942

6.  Adenosine Deaminase That Acts on RNA 3 (ADAR3) Binding to Glutamate Receptor Subunit B Pre-mRNA Inhibits RNA Editing in Glioblastoma.

Authors:  Eimile Oakes; Ashley Anderson; Aaron Cohen-Gadol; Heather A Hundley
Journal:  J Biol Chem       Date:  2017-02-06       Impact factor: 5.157

7.  CRM1 mediates the export of ADAR1 through a nuclear export signal within the Z-DNA binding domain.

Authors:  H Poulsen; J Nilsson; C K Damgaard; J Egebjerg; J Kjems
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

8.  Specificity of ADAR-mediated RNA editing in newly identified targets.

Authors:  Eva M Riedmann; Sandy Schopoff; Jochen C Hartner; Michael F Jantsch
Journal:  RNA       Date:  2008-04-22       Impact factor: 4.942

9.  Site-directed RNA repair of endogenous Mecp2 RNA in neurons.

Authors:  John R Sinnamon; Susan Y Kim; Glen M Corson; Zhen Song; Hiroyuki Nakai; John P Adelman; Gail Mandel
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-16       Impact factor: 11.205

10.  Differential inhibition of RNA editing in hepatitis delta virus genotype III by the short and long forms of hepatitis delta antigen.

Authors:  Qiufang Cheng; Geetha C Jayan; John L Casey
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.